{"id":"mitomycin-and-doxifluridine","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mitomycin is a mitomycin C derivative that functions as a DNA cross-linking agent, creating interstrand DNA adducts that prevent replication and transcription. Doxifluridine is a prodrug of 5-fluorouracil that inhibits thymidylate synthase and incorporates into RNA and DNA, disrupting nucleotide synthesis. The combination targets rapidly dividing cancer cells through complementary mechanisms of DNA damage and antimetabolite activity.","oneSentence":"Mitomycin and doxifluridine work synergistically as a chemotherapy combination, with mitomycin acting as an alkylating agent and doxifluridine as a fluoropyrimidine antimetabolite to inhibit DNA synthesis and induce cancer cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:41.075Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT00296322","phase":"PHASE3","title":"Trial of Adjuvant Chemotherapy for Gastric Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2001-10","conditions":"Stomach Cancer","enrollment":528},{"nctId":"NCT00296335","phase":"PHASE3","title":"Trial of Adjuvant Chemotherapy for Gastric Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2002-02","conditions":"Stomach Cancer","enrollment":855}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Mitomycin and doxifluridine","genericName":"Mitomycin and doxifluridine","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mitomycin and doxifluridine work synergistically as a chemotherapy combination, with mitomycin acting as an alkylating agent and doxifluridine as a fluoropyrimidine antimetabolite to inhibit DNA synthesis and induce cancer cell death. Used for Gastric cancer (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}